Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The hepatic flaviviridae: summary.

S Sherlock1

  • 1Royal Free Hospital School of Medicine, Royal Free Hospital, Pond Street, London, UK.

Journal of Viral Hepatitis
|April 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis.

Clinics in liver disease·2001
Same author

A la carte interferon for hepatitis C?

Hepatology (Baltimore, Md.)·2000
Same author

Biotechnologies and liver diseases.

Forum (Genoa, Italy)·1999
Same author

Carbon dioxide embolism following diagnostic hysteroscopy.

Anaesthesia and intensive care·1999
Same author

Focal nodular hyperplasia in a young female.

Journal of hepatology·1999
Same author

Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity?

Mayo Clinic proceedings·1998

Hepatitis C virus (HCV) envelope proteins elicit antibodies, but vaccine development is hindered by viral diversity and inadequate immune responses. Combination therapy with interferon and ribavirin shows promise for treating chronic Hepatitis C infection.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) envelope proteins E1 and E2 induce neutralizing antibodies, yet vaccine development remains challenging due to significant viral sequence diversity.
  • The host's immune response, including cellular and humoral immunity, is insufficient to clear HCV, often leading to chronic infection and disease progression.
  • Factors such as age at infection and co-existing conditions influence the natural history of HCV, with transfusion-related transmission generally having a poorer prognosis.

Purpose of the Study:

  • To review the challenges in developing an effective Hepatitis C virus (HCV) vaccine.
  • To discuss the host immune response to HCV and its limitations in viral clearance.
  • To evaluate current and emerging therapeutic strategies for chronic Hepatitis C.

Related Experiment Videos

Main Methods:

  • Review of existing literature on HCV pathogenesis, immunology, and therapeutic interventions.
  • Analysis of data regarding vaccine development approaches, including plasmid vaccines and virus-like particles.
  • Assessment of clinical outcomes for interferon-based monotherapy and combination therapy with ribavirin.

Main Results:

  • Despite the induction of neutralizing antibodies by HCV envelope proteins, prolonged protective immunity for vaccines has not been achieved.
  • Interferon therapy yields sustained responses in approximately 30% of patients, with combination therapy showing improved outcomes.
  • Ribavirin monotherapy improves liver histology and transaminase levels, with enhanced benefits when combined with interferon, potentially due to immunomodulatory effects.

Conclusions:

  • Developing a successful HCV vaccine is complicated by viral diversity and the inadequacy of the natural immune response.
  • Current treatment strategies, particularly the combination of interferon and ribavirin, offer improved efficacy for managing chronic Hepatitis C.
  • Further research is needed to clarify the long-term benefits of interferon therapy in preventing liver disease progression and the precise mechanisms of ribavirin's action.